EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials

Julien Taieb iD, John Souglakos, Ioannis Boukovinas iD, Antoine Falcoz, Franck Pages iD, Ippokratis Messaritakis iD, Jaafar Bennouna, Pascal Artru iD, Christophe Louvet, Celine Lepere, Jean Francois Emile iD, Olivier Bouche iD und 10 weitere

Journal of Clinical Oncology · 2025-05 · 43 (13) · 1564-1577

DOI: 10.1200/jco.24.00648 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-05. Verfasst von Julien Taieb und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, CARPEM Comprehensive Cancer Center, Georges-Pompidou European Hospital, AP-HP, Paris, F…. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colonic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here, we analyzed the prognostic value of the two biomarkers in patients who participated in the randomized phase III IDEA-France and HORG trials. METHODS Plasma samples were collected after surgery and before adjuvant chemotherapy. ctDNA analysis was performed using a clinically validated, personalized, tumor-informed 16-plex protein chain reaction assay. Multivariable analyses for time to recurrence (TTR; patients without recurrence or death due to CC) and overall survival (OS) were performed using ctDNA and IS results, along with other parameters including treatment duration and disease risk group. RESULTS Of the 554 patients with available ctDNA results, 445 were ctDNA-negative (80.3%) and 109 were ctDNA-positive (19.7%); baseline characteristics showed more T4/N2 and venous embolism/lymphatic invasion/perineural invasion+ in ctDNA-positive patients. With a median follow-up of 6.7 years, the 2-year TTR rate was 43.5% (95% CI, 34.1 to 52.6) for ctDNA-positive patients and 88.1% (95% CI, 84.7 to 90.8) for ctDNA-negative patients ( P < .0001). ctDNA was confirmed as an independent prognostic marker for both TTR (adjusted hazard ratio [adjHR], 5.21 [95% CI, 3.59 to 7.58]; P < .001) and OS (adjHR, 4.84 [95% CI, 3.40 to 6.89]; P < .001). ctDNA remained the most significant prognostic factor irrespective of disease stage, treatment duration, and IS results. IS was not prognostic in ctDNA-positive patients but remained a significant prognostic tool for ctDNA-negative patients. CONCLUSION In this combined analysis of two adjuvant trials dedicated to patients with stage III CC after surgery, ctDNA was detectable in 19.7% of the patients and was confirmed as a major independent prognostic biomarker. IS seems to bring additional prognostic information in the 80.3% of patients who are ctDNA-negative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColonic NeoplasmsBiomarkers, TumorHumansMaleFemaleAgedMiddle AgedNeoplasm StagingPrognosisChemotherapy, AdjuvantFranceAdult

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastroenterology and Gastrointestinal Oncology, CARPEM Comprehensive Cancer Center, Georges-Pompidou European Hospital, AP-HP, Paris, France.
  • SIRIC CARPEM, Université Paris-Cité, Paris, France.
  • Centre de Recherche des Cordeliers, INSERM, CNRS, Université Paris-Cité, Sorbonne Université, USPC, Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
  • Department of Medical Oncology, University Hospital of Heraklion, Crete, Greece.
  • Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, Greece.
  • Oncology Unit, Bioclinic, Thessaloniki, Greece.

ORCID-Profile: Julien Taieb, Ioannis Boukovinas, Franck Pages, Ippokratis Messaritakis, Pascal Artru, Jean Francois Emile, Olivier Bouche, Minetta C Liu, Thierry André, Jérome Galon, Pierre Laurent-Puig

Zitieren

APA

Taieb, J., Souglakos, J., Boukovinas, I., Falcoz, A., Pages, F., Messaritakis, I., Bennouna, J., Artru, P., Louvet, C., Lepere, C., Emile, J. F., Bouche, O., Mazard, T., Vernerey, D., Vogiatzoglou, K., Tzardi, M., Sharma, S., Liu, M. C., Sethi, H., …, & Laurent-Puig, P. (2025). Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials. Journal of Clinical Oncology, 43(13), 1564-1577. https://doi.org/10.1200/jco.24.00648

Vancouver

Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, et al. Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials. Journal of Clinical Oncology. 2025;43(13):1564-1577. doi:10.1200/jco.24.00648

BibTeX
@article{Taieb2025,
  author = {Taieb, Julien and Souglakos, John and Boukovinas, Ioannis and Falcoz, Antoine and Pages, Franck and Messaritakis, Ippokratis and Bennouna, Jaafar and Artru, Pascal and Louvet, Christophe and Lepere, Celine and Emile, Jean Francois and Bouche, Olivier and Mazard, Thibault and Vernerey, Dewi and Vogiatzoglou, Konstantinos and Tzardi, Maria and Sharma, Shruti and Liu, Minetta C and Sethi, Himanshu and André, Thierry and Galon, Jérome and Laurent-Puig, Pierre},
  title = {Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {13},
  pages = {1564--1577},
  doi = {10.1200/jco.24.00648}
}
Kostenlos starten →